CrossAssetDataThe Company File
···
ICUI

ICU Medical, Inc.

ICU Medical, Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in San Clemente, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2.2 billion and a profit of $732 thousand (its filed statements).

Product business Surgical & Medical Instruments & Apparatus San Clemente, CA filings since 1995 9 of 9 filed
Ask the desk about ICUI → Compare ICUI with WST → Price chart on TradingView ↗ Full EDGAR file ↗ Watch ICUI →

Sector peers: WSTIARTMMEDPODD

5.2/10headline grade
vs its business-model standard
5.6/10past 6.2/10present 3.3/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.2 out of ten, 9 of 9 metrics filed: past 5.6 out of ten, present 6.2 out of ten, future 3.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 6.3 out of ten. 2 warning events since 2017; the latest 2018-03-02. 63rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.5 out of ten. +21.8% a year over 10 filed years; profitable in 7 of 10. 55th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 4.8 out of ten. Share count grew 1.4% a year. 5% of cash flow returned. Insiders: 19 sales, 0 purchases. 48th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.4 out of ten. ROE 0%: 0¢ of profit per shareholder dollar. Leverage 48%: owes 48¢ per asset dollar. 54th percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 5.9 out of ten. top 41% of 109 in its family; net margin 0%. 59th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 8.3 out of ten. top 17% of 90 in its family for leadership; chief executive since 2014. 83rd percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 2.9 out of ten. bottom 29% of 104 in its family for room to expand. 29th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 2.6 out of ten. bottom 26% of 105 in its family for growth drivers. 26th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.1 out of ten. top 49% of 88 in its family for expectations against reality. 51st percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-19 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 144, 2026-09-03. Filings on record since 1995. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Infusion Consumables 50%, Infusion Systems 31%, Vital Care 20%. By geography: United States 61%, EMEA 19%, APAC 10%, Other foreign countries 10%. As tagged in its annual report (Form 10-K, filed 2026-02-19).

Who runs it

Jain, Vivek (Chairman and CEO); Bonnell, Brian Michael (Chief Financial Officer); Voigtlander, Christian B. (Chief Operating Officer); Sousa, Ben (Chief Information Officer); Sanzone, Virginia Ruth (VP, General Counsel); Woolson, Daniel (VP, GM-Infusion Capital); Finney, Elisha W (director); Abbey, Donald (director); Greenberg, David C. (director); Hernandez, Laurie (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.